DHR · NYQ · Healthcare
Danaher Corporation
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 125.82
Market price
USD 227.97
Implied upside
-44.8%
10-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case · Price 2026-11-02 · Accounts to 2025-12-31
Current EV/EBITDA of 24.6x sits outside a defensible 3-20x band, so the exit multiple is capped at 20.0x. A multiple that far out usually means EBITDA is the wrong denominator for this business.
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY26 | FY27 | FY28 | FY29 | FY30 | FY31 | FY32 | FY33 | FY34 | FY35 | CAGR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | USD 26.3bn | USD 28.3bn | USD 30.3bn | USD 32.2bn | USD 34.1bn | USD 35.8bn | USD 37.4bn | USD 38.8bn | USD 40.0bn | USD 41.0bn | +5.1% |
| EBIT | USD 5.9bn | USD 6.3bn | USD 6.8bn | USD 7.2bn | USD 7.6bn | USD 8.0bn | USD 8.4bn | USD 8.7bn | USD 9.0bn | USD 9.2bn | +5.1% |
| NOPAT | USD 5.0bn | USD 5.3bn | USD 5.7bn | USD 6.1bn | USD 6.4bn | USD 6.8bn | USD 7.1bn | USD 7.3bn | USD 7.6bn | USD 7.8bn | +5.1% |
| Add depreciation & amortisation | USD 2.4bn | USD 2.6bn | USD 2.8bn | USD 3.0bn | USD 3.1bn | USD 3.3bn | USD 3.4bn | USD 3.6bn | USD 3.7bn | USD 3.8bn | +5.1% |
| Less capital expenditure | USD -1.3bn | USD -1.6bn | USD -1.9bn | USD -2.2bn | USD -2.5bn | USD -2.9bn | USD -3.2bn | USD -3.6bn | USD -3.9bn | USD -4.2bn | +13.6% |
| Capex, % of revenue | 5.1% | 5.7% | 6.3% | 6.9% | 7.5% | 8.0% | 8.6% | 9.2% | 9.8% | 10.4% | - |
| Less increase in working capital | USD -316.3m | USD -377.6m | USD -372.4m | USD -361.9m | USD -345.9m | USD -324.5m | USD -297.6m | USD -265.4m | USD -228.4m | USD -187.0m | -5.7% |
| Free cashflow to firm | USD 5.7bn | USD 6.0bn | USD 6.2bn | USD 6.5bn | USD 6.7bn | USD 6.9bn | USD 7.0bn | USD 7.1bn | USD 7.1bn | USD 7.1bn | +2.4% |
| Discount factor | 0.9617 | 0.8895 | 0.8227 | 0.7610 | 0.7038 | 0.6510 | 0.6021 | 0.5569 | 0.5151 | 0.4764 | - |
| Present value | USD 5.5bn | USD 5.3bn | USD 5.1bn | USD 4.9bn | USD 4.7bn | USD 4.5bn | USD 4.2bn | USD 3.9bn | USD 3.7bn | USD 3.4bn | - |
| Present Value Of The Forecast | USD 45.3bn | ||||||||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 4.89% | US 10-year Treasury (^TNX), 2026-11-02 |
| Equity risk premium | 4.23% | Damodaran, January 2026 |
| Beta | 0.868 | Reported 0.803, pulled toward 1.0 (Blume) |
| Cost of equity | 8.57% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.29% | Risk-free + 40bp, the spread for a AAA rating at 17.7x interest cover. Book interest / average debt was lower, at 1.4%. |
| Market capitalisation | USD 160.3bn | 89.1% of capital |
| Total debt | USD 19.7bn | 10.9% of capital, book value as a proxy |
| Tax rate | 15.5% | Effective, capped at statutory |
| WACC | 8.12% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
57% of EV
- Forecast FCFF, final year
- USD 7.1bn
- Capex at depreciation, working capital in reinvestment
- USD 10.0bn
- Less reinvestment at g/ROIC (30.8% of NOPAT)
- USD -3.1bn
- Capitalised
- USD 6.9bn
- ROIC (WACC floor)
- 8.1%
- Terminal value, undiscounted
- USD 125.7bn
- Terminal value, discounted
- USD 59.9bn
- Enterprise value
- USD 105.2bn
- Less net debt
- USD 15.1bn
- Equity value
- USD 90.1bn
Exit at 20.0x EBITDA
73% of EV
- Terminal value, undiscounted
- USD 259.4bn
- Terminal value, discounted
- USD 123.6bn
- Enterprise value
- USD 168.8bn
- Less net debt
- USD 15.1bn
- Equity value
- USD 153.8bn
Spread between methods: 52%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 6.12% | 182.41 | 179.91 | 177.47 | 175.14 | 172.98 |
| 7.12% | 151.97 | 149.70 | 147.43 | 145.15 | 142.88 |
| 8.12% | 129.58 | 127.70 | 125.82 | 123.93 | 122.05 |
| 9.12% | 112.18 | 110.59 | 109.00 | 107.42 | 105.83 |
| 10.12% | 98.27 | 96.91 | 95.56 | 94.20 | 92.85 |
Outlined: this model. Green text: above today's price of 227.97. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Actual | Model | Implied | Gap |
|---|---|---|---|---|
| Revenue growth, a year | -2.7% | 5.3% | 12.0% | |
| EBIT margin | 28.3% | 22.4% | 41.9% | |
| Discount rate | - | 8.1% | 5.3% |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.